Description: Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Home Page: www.evogene.com
13 Gad Feinstein Street
Rehovot,
7414002
Israel
Phone:
972 8 931 1900
Officers
| Name | Title |
|---|---|
| Mr. Ofer Haviv CPA | CEO & Pres |
| Mr. Mark Kapel | Chief Technology Officer |
| Dr. Elran Hillel Haber M.B.A., Ph.D. | Chief Exec. Officer of Biomica Ltd |
| Mr. Yaron Eldad | Chief Financial Officer |
| Dr. Eyal Emmanuel | Chief Scientific Officer |
| Mr. Sassi Masliah | Exec. VP of Corp. Devel. |
| Ms. Liat Foigel Wejgman | VP of HR |
| Dr. Nir Arbel | Chief Product Officer |
| Mr. Dotan Borenstein | Chief Bus. Officer of Lavie Bio Ltd. |
| Mr. Eyal Ronen | Exec. VP of Bus. Devel. |
Exchange: TA
Country: IL
Currency: Israeli Agora (ILA)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9347 |
| Price-to-Sales TTM: | 73.0137 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 133 |